Skip to main content
. Author manuscript; available in PMC: 2019 Dec 18.
Published in final edited form as: Life Sci. 2019 Feb 7;221:1–12. doi: 10.1016/j.lfs.2019.02.014

Fig. 4.

Fig. 4.

Inhibition of EPAC1 interrupts ANXA2 binding to lipid rafts and ANXA2 association with S100A10 in HUVECs. WB shows decreased levels of associated ANXA2 in S100A10 precipitates in ESI09-treated HUVECs (n = 3), compared with vehicle-treated HUVECs (n = 3) (A) (P < 0.05). ANXA2 levels were presented as percentages of the indicated loading controls in densitometry. Significantly reduced ANXA2 was detected in lipid rafts from ESI09-treated HUVECs (n = 3), compared with vehicle-treated group (n = 3) (B) (P < 0.01). A cell lysate was used as positive control. ANXA2 levels were presented as percentages of the positive controls in densitometry. Equal loading amounts of proteins were confirmed with lipid raft- and non-lipid raft-specific assays (Fig. S7). All experiments were repeated three times.